Hipertansif hastalarda N- amino terminal prohormon beyin natriüretik peptid düzeyleri ile ilişkili faktörler

Abstract

Amaç: N- amino terminal prohormon beyin natriüretik peptid (NT-pro BNP) ise genel popülasyonda hem kalp yetersizliği gelişimi hem de kardiyovasküler olay gelişiminin öngörücüsüdür. Biz bu çalışmada hipertansif hasta toplumunda NT-pro BNP düzeyini etkileyen faktörleri araştırdık. Yöntemler: Çalışmaya yaş ortalaması 50,5 ± 10,7 olan toplam 309 hipertansif hasta alındı. Hastaların % 49,2 erkeklerden oluşmaktaydı. NT-pro BNP değeri 60 pg/dl ‘nın üzerinde olanlar yüksek grup (110 kişi) 60 ve altında olanlar ise düşük grup olarak belirlendi (199 kişi). Kalp yetersizliği, orta-ileri kapak hastalığı, koroner arter hastalığı, aritmi, kronik böbrek yetersizliği, kronik obstrüktif akciğer hastalığı olanlar ve sekonder hipertansiyonu olan hastalar çalışmaya alınmadı. Bulgular: Sol ventrikül kitle indeksi, 24 saatlik, gündüz ve gece sistolik kan basıncı ve gece diyastolik kan basıncı yüksek grupta daha yüksek ölçülmüştü. Stepwise liner regresyon analizinde, cinsiyet, sol ventrikül kitle indeksi, yaş ve gece sistolik kan basıncının yüksek NT-pro BNP düzeylerinin bağımsız öngörücüleri oldukları tespit edildi (sırasıyla, R²=0.236, ß= -0,258, P

Keywords

• NT-pro BNP, hipertansiyon, Türk toplumu

Factors associated with the levels of N- amino terminal prohormone brain natriuretic peptid in hypertensive population

Abstract

Objectives: In this study we ınvestigated that which the factors affecting the level of N- amino terminal prohormone brain natriuretic peptid (NT-pro BNP) in hypertensive population. Methods: A total of 309 hypertensive patients (mean age 50.5 ± 10.7, 49.2% male) were enrolled into the study. Lower group was defined as NT-pro BNP 60 pg/dl or low, high group was defined as NT-pro BNP 60 pg/dl higher. The patients with secondary hypertensive, heart failure, coronary artery disease, valvular diseases, chronic renal failure (serum creatinine >1.5 mg/dl, blood urea nitrogen>30 mg/dl) and chronic obstructive pulmonary disease were excluded from the study. Results: Left ventricular mass index, 24-h systolic blood pressure, day systolic blood pressure, night systolic blood pressure and night diastolic blood pressure higher in high group than lower group. In stepwise linear regression analysis, a significant relation was found between sex, left ventricular mass index, age, night systolic blood pressure and higher NT-pro BNP levels (R²=0.236, ß= -0.258, P

Keywords

• NT-pro BNP, hypertension, Turkish society

References

1. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002;287:1003- 1010.
2. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hyper- tension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988- 1991. Hypertension 1995;25:305-313.
3. Palmer A, Bulpitt C, Beevers G, et al. Risk factors for isch- aemic heart disease and stroke mortality in young and old hypertensive patients. J Hum Hypertens 1995;9:695-697.
4. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557-1562.
5. Wilhelmsen L, Rosengren A, Eriksson H, et al. Heart failure in the general population of men—morbidity, risk factors and prognosis. J Intern Med. 2001;249:253-261.
6. Vickery S, Price CP, John RI, et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relation-ship to renal function and left ventricular hypertro- phy. Am J Kidney Dis 2005;46:610-620.
7. Wiese S, Breyer T, Dragu A, et al. Gene ex-pression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation 2000;102:3074-3079.
8. Kistorp C, Raymond I, Pedersen F,et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as pre-dictors of mortality and cardiovascular events in older adults. JAMA 2005; 293: 1609-1616.

9. O’Brien E, Asmar R, Beilin L,et al. on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self-blood pressure measurement. J Hypertens 2005;23:697-701.
10. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26:S5-20.
11. Devereux R, Koren M, de Simone G, et al. Methods forde- tection of left ventricular hypertrophy: application to hyper- tensive heart disease. Eur Heart J 1993;14:8-15.
12. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976-82.
13. Willis MS, Lee ES, Grenache DG: Effect of anemia on plasma concentrations of NT- proBNP. Clin Chim Acta 2005;358:175-181.
14. Knudsen CW, Clopton P, Westheim A, et al. Predictors of elevated B-type natriuretic peptide concentrations in dys- pneic patients without heart failure: an analysis from the breathing not properly multinational study. Ann Emerg Med 2005;45:573-580.
15. Wu AH, Omland T, Wold Knudsen C, et al. Relationship of B-type natriuretic peptide and anemia in patients with and without heart failure: a substudy from the Breathing Not Properly (BNP) Multinational Study. Am J Hematol 2005;80:174-180.
16. S.Yi, G.Contreras, E.R Miller, et al. Correlates of N-termi- nal prohormone Brain natriuretic peptides in African Amer- icans with Hypertensive Chronic Kidney Disease :The af- rican American Study of kidney Disease and Hypertension. Am J Nephrol 2009;29:292-298.
17. Bayes-Genis A, DeFilippi C, Januzzi JL. Understanding amino-terminal pro-B-type natriuretic peptide in obesity. Am J Cardiol 2008;101:89-94.
18. Olsen MH, Hansen TW, Christensen MK, et al. N-terminal pro brain natriuretic peptide is inversely related to metabol- ic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005;46:660-666.
19. Lee K, Kim J, Koh S, et al. N-terminal pro BNP levels in the Korean general population. Korean Circ J 2010;40:645-650.
20. Silverberg D, Wexler D, Blum M, et al. The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens 2004;13: 63-170.
21. Stehouwer CDA, Smulders YM. Microalbuminuria and risk forcardiovascular disease: analysis of potential mecha- nisms. J Am Soc Nephrol 2006;17:2106-2111.
22. Vishram JK, Borglykke A, Andreasen AH, et al. on behalf of the MORGAM Project. Impact of Age on the Importance of Systolic and Diastolic Blood Pressures for Stroke Risk: The Monica, Risk, Genetics, Archiving and Monograph (MORGAM) Project. Hypertension 2012;60:1117-1123
23. Fagard RH, Celis H, Thijs L, et al. Daytime and night- time blood pressure as predictors of death and cause-spe- cific cardiovascular events in hypertension. Hypertension 2008;51:55-61.
24. Hansen TW, Li Y, Boggia J, et al. Predictive role of the night-time blood pressure. Hypertension 2011;57:3-10.
25. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-352.
26. Levy D, Garrison RJ, Savage DD, et al. Prognostic impli- cations of echocardiographically determined left ventricu- lar mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-1566.
27. Hildebrandt P, Boesen M, Olsen M, et al. N-terminal pro brain natriuretic peptide in arterial hypertension-a marker for left ventricular dimensions and prognosis. Eur J Heart Fail 2004;6:313-317.
28. Joles JA, Koomans HA. Causes and consequences of in- creased sympathetic activity in renal disease. Hypertension 2004;43:699-706.
29. Esler M. The sympathetic system and hypertension. Am J Hypertens 2000;13(6 Pt 2):99S-105S.
30. Bruch C,Fischer C,Sinderman J et al. Comparison of the prognostic usefulness of N-terminal pro-brain natriuretic peptide in patients with heart failure with versus without chronic kidney disease. Am J Cardiol 2008;102:469-74.
31. Wang HS, Yoo BS, Chung IY, et al. Is B-type natriuretic peptide (BNP) measurement useful test for diagnosing sys- tolic heart failure in patients with moderate to severe renal insufficiency? Korean Circ J 2005;35:897-903.
32. Olsen MH, Wachtell K, Nielsen OW, et al. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: A LIFE substudy. J Hypertens2006;24:1531-1539.